<DOC>
	<DOCNO>NCT02039674</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , efficacy pembrolizumab ( MK-3475 ) combination chemotherapy immunotherapy participant unresectable metastatic non-small cell lung cancer ( NSCLC</brief_summary>
	<brief_title>A Study Pembrolizumab ( MK-3475 ) Combination With Chemotherapy Immunotherapy Participants With Lung Cancer ( MK-3475-021/KEYNOTE-021 )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Stage IIIb/IV NSCLC Disease progression &gt; 1 year complete adjuvant therapy Stage IIIIA disease systemic therapy recurrent disease Resolution toxic effect ( except alopecia ) recent therapy At least one radiographically measurable lesion Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Status scale Female participant reproductive potential must pregnant ( negative urine serum human chorionic gonadotropin test within 72 hour study start ) Female male participant reproductive potential must agree use adequate contraception throughout study period 120 day last dose study therapy 180 day last dose chemotherapeutic agent tyrosine kinase inhibitor Currently participate participate study investigational agent use investigational device within 4 week administration pembrolizumab Expected require form antineoplastic therapy study Is chronic systemic steroid therapy form immunosuppressive medication Has receive livevirus vaccination within 30 day plan treatment start Clinically active diverticulitis , intraabdominal abscess , gastrointestinal ( GI ) obstruction , abdominal carcinomatosis ( known risk factor bowel perforation ) History hematologic malignancy , primary brain tumor sarcoma , another primary solid tumor , unless participant undergone potentially curative therapy evidence disease 5 year Active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Severe hypersensitivity reaction treatment another monoclonal antibody ( mAb ) Active autoimmune disease require systemic treatment past 2 year ( replacement therapy hormone deficiency allow ) Prior treatment antiprogrammed cell death protein1 ( antiPD1 ) , PD Ligand1 ( PDL1 ) PD Ligand2 ( PDL2 ) agent antibody target immunoregulatory receptor mechanisms Systemic cytotoxic chemotherapy , antineoplastic biologic therapy , major surgery within 3 week first dose study medication Radiation therapy lung &gt; 30 Gy within 6 month first dose study medication Prior tyrosine kinase inhibitor therapy palliative radiation within 7 day first dose study medication Active infection require therapy History Human Immunodeficiency Virus ( HIV ) Active Hepatitis B C Symptomatic ascites pleural effusion Interstitial lung disease pneumonitis require oral IV glucocorticoid Pregnant breastfeeding , expect conceive father child within project duration study Psychiatric disorder substance ( drug/alcohol ) abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD-1</keyword>
	<keyword>PD1</keyword>
	<keyword>Programmed Cell Death-1</keyword>
	<keyword>Programmed Cell Death 1</keyword>
</DOC>